Experimental models of inflammatory bowel diseases

  • Kiesler P
  • Fuss I
  • Strober W
  • 5


    Mendeley users who have this article in their library.
  • 0


    Citations of this article.


Therapeutic advances occurred these last years rather for Crohn's disease than for ulcerative colitis. For Crohn's disease the impressive effectiveness of infliximab is confirmed; thalidomide is considered as an outsider, long-term safety for both treatments is still of great concern. For ulcerative colitis use of probiotics could be promising; practical modalities in use of mesalazine and ciclosporine are better defined.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Patricia Kiesler

  • Ivan J. Fuss

  • Warren Strober

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free